Imaging SV2A in Mood Disorders with Ketamine
This study is looking at how a protein called SV2A, found in brain connections (synapses), might be different in people with Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). We also want to see if ketamine, a medication, can help restore these brain connections. You would have an MRI and 2-3 PET scans (a type of imaging) to look at your brain, with ketamine given during one of the scans. We hope to find out if changes in SV2A are linked to these conditions and if ketamine can improve them, potentially leading to better antidepressant responses. The study plans to enroll 130 participants aged 18-70 who speak English and have MDD or PTSD. The study's status is currently unclear.
- Study design
- This is an interventional study planning to enroll 130 participants. It aims to compare SV2A availability in different groups and see how ketamine affects it.
- What's involved
- You would undergo an MRI and 2-3 PET scans, with ketamine administered for one of the PET scans. Cognitive testing and a stress test may also be done on scan days.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints will be measured through the study completion date, which is an average of 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Imaging SV2A in Mood Disorders
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Irina Esterlis, PhD · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Evidence of synaptic changes in psychiatric disorders confirmed by PET data.Through study completion date, an average of 5 years.
- Evidence of synaptic density at time of its greatest anti-depressant response in psychiatric disorders confirmed with PET data.Through study completion date, an average of 5 years.